213人 A new study has revealed a promising new treatment method for late-stage non-small cell lung cancer (NSCLC). The research, published in the Annals of Oncology, compared the efficacy and safety of two different treatments: nanoparticle polymeric micellar paclitaxel (pm-Pac) plus cisplatin ...
New Lung Cancer Treatment Hope after Major Breakthrough by Scots ScientistsByline: MATT DICKINSONDaily Mail (London)
Cullinan Oncology announced that the FDA has granted Breakthrough Therapy Designation for CLN-081 for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) harboring epidermal growth factor (“EGFR”) exon 20 in...
Around 40,000 people are diagnosed annually with lung cancer in the UK, and SCLC accounts for nearly one in five of all these cases. Unfortunately, the prognosis for SCLC patients is very bleak – two thirds of people are diagnosed in the late stages of the disease when the five year sur...
Although immunotherapy has achieved remarkable breakthrough in lung cancer treatment, patients with mutant p53 expressing lung cancers only show limited responses to immunotherapies. This highlights the urgent need for novel therapeutic approaches to enhance the efficacy of immunotherapies. p53 mutations often...
Chimeric antigen receptor (CAR)-T cell adoptive immunotherapy is a promising cancer treatment that uses genetically engineered T cells to attack tumors. However, this therapy can have some adverse effects. CAR-T cell-derived exosomes are a potential alte
"c-MYC is linked to the majority of cancer types. Its dynamic structure has made it difficult to design drugs that affectprotein function," says Professor Marie Arsenian Henriksson. "Our breakthrough through the identification of a switch between the active and inactive forms of c-MYC allows us...
The Japanese company scored with Veozah, a breakthrough treatment for hot flashes and night sweats. It also won approval for Izervay, a treatment for geographic atrophy that it acquired in its $5.9 billion buyout of Iveric Bio in early 2023. Both Veozah and Izervay have bee...
How do the average direct costs for Nonsmall Cell Lung Cancer (NSCLC) patients in Italy vary by stage in the first year post-diagnosis? What improvements in treatment outcomes for early-stage Nonsmall Cell Lung Cancer (NSCLC) are anticipated due to new systemic options?
, AstraZeneca, said: “Having now treated more than one million patients around the world, TAGRISSO has repeatedly transformed expectations for patients with EGFR-mutated lung cancer by not only extending survival but also showing it...